News
Oral Laquinimod Reduced MS Relapses by 23%
Major Finding: Patients taking the investigational oral drug laquinimod reduced their annualized rate of multiple sclerosis relapse by 23% after 2...
The results of the ALLEGRO phase III trial of laquinimod for relapsing-remitting multiple sclerosis are now published in full in the March 15 New England Journal of Medicine (N. Engl. J. Med. 2012;366:1000-9). We previously reported on the results of ALLEGRO at last year’s annual meeting of the American Academy of Neurology (See sidebar). The full paper does not contain any notable revisions from our original report.
Last fall, we also reported (see sidebar, as well) on the results of the second phase III trial of laquinimod, BRAVO, at the joint triennial congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis. The results have not been published yet.